Company profile · Biotech & medical
Alar Pharmaceuticals
昱展新藥生技股份有限公司 · 6785
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Alar Pharmaceuticals engages in new drug research and development.[1]
The company develops long-acting injectable formulations and novel treatments including ALA-3000 for treatment-resistant depression, ALA-1000 for opioid use disorder and osteoarthritis pain in dogs, and Bupanlar as an osteoarthritis analgesic.[2]
Alar Pharmaceuticals is based in Taichung, Taiwan.[1]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$0m | -100.0% | – |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$4m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | Alar Pharmaceuticals Inc. |
|---|---|
| Chinese name | 昱展新藥生技股份有限公司 |
| Stock code | 6785 (TPEx) |
| Industry | Biotech & medical |
| Founded | 23 Sep 2016 |
| Listed | 24 Jan 2024 |
| Paid-in capital | NT$668m |
| Chairman | 林東和 |
| President | 文永順 |
| Headquarters | 5F., No.32, Keya Rd., Daya Dist. Taichung City, Taiwan (R.O.C.) |
| Website | https://www.alarpharm.com |
| Official business description | 新藥研發 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 昱展新藥生技股份有限公司 · mops · retrieved 04 Nov 2026
- History&Milestones – 昱展新藥生技股份有限公司 · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list